King of Prussia, PA – January 2025 – OCMS Bio, a leader in monoclonal antibody discovery, is pleased to announce the appointment of Dr. Pavel Nikitin as Chief Development Officer. In this role, Dr. Nikitin will lead the advancement of OCMS Bio’s preclinical assets, guiding them toward clinical development and commercialization.

Dr. Nikitin brings extensive experience in biopharmaceutical development, with a strong track record in translating early-stage research into impactful therapeutics. His expertise in immunotechnology, antibody engineering, and preclinical strategy will be instrumental in expanding OCMS Bio’s pipeline of novel monoclonal antibodies for infectious diseases, oncology, and autoimmune disorders.

“We are thrilled to welcome Pavel to our leadership team,” said Dr. Scott Dessain, Chief Scientific Officer of OCMS Bio. “His experience in advancing therapeutic candidates from discovery to clinical readiness will be invaluable as we focus on bringing our preclinical assets closer to patients.”

As OCMS Bio continues to build a robust pipeline of therapeutic antibodies, Dr. Nikitin’s leadership will play a key role in shaping the company’s future growth and success.

For more information, visit ocms.bio.

Media Contact:
Thomas Halpern
COO
OCMS Bio
info@ocms.bio
678-626-7246